Rosen Law Firm reminded purchasers of Aardvark Therapeutics, Inc. securities that Oct. 13, 2026, is the deadline to seek appointment as lead plaintiff in a filed securities class action. The notice covers common stock issued pursuant or traceable to Aardvark's Feb. 13, 2025, initial public offering and securities purchased from Feb. 13, 2025, through May 14, 2026, inclusive. The lawsuit alleges that the company's Registration Statement and other public statements failed to disclose that ARD-101 was less safe than represented, overstating its clinical, regulatory and commercial prospects. Investors may seek information through Rosen Law Firm's website, Phillip Kim, Esq., or the firm's email contact, and may be eligible for compensation without out-of-pocket fees or costs under a contingency fee arrangement. No class has been certified; investors may retain counsel, remain absent class members or seek lead plaintiff status, and eligibility for any future recovery does not depend on serving as lead plaintiff.